Kimelman & Baird’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $942K | Hold |
15,525
| – | – | 0.08% | 74 |
|
|
2025
Q4 | $837K | Sell |
15,525
-5,072
| -25% | -$244K | 0.06% | 77 |
|
|
2025
Q3 | $929K | Sell |
20,597
-650
| -3% | -$30.4K | 0.07% | 70 |
|
|
2025
Q2 | $984K | Sell |
21,247
-100
| -0.5% | -$4.91K | 0.08% | 70 |
|
|
2025
Q1 | $1.3M | Hold |
21,347
| – | – | 0.11% | 58 |
|
|
2024
Q4 | $1.21M | Hold |
21,347
| – | – | 0.1% | 67 |
|
|
2024
Q3 | $1.1M | Sell |
21,347
-1,085
| -5% | -$50.9K | 0.09% | 69 |
|
|
2024
Q2 | $932K | Buy |
+22,432
| New | +$1M | 0.08% | 73 |
|
|
2021
Q2 | $901K | Buy |
+13,490
| New | +$880K | 0.08% | 65 |
|
|
2019
Q3 | $2.22M | Sell |
43,707
-161
| -0.4% | -$7.57K | 0.31% | 50 |
|
|
2019
Q2 | $1.99M | Sell |
43,868
-13,635
| -24% | -$635K | 0.28% | 51 |
|
|
2019
Q1 | $2.74M | Hold |
57,503
| – | – | 0.39% | 45 |
|
|
2018
Q4 | $2.99M | Hold |
57,503
| – | – | 0.47% | 45 |
|
|
2018
Q3 | $3.57M | Hold |
57,503
| – | – | 0.45% | 46 |
|
|
2018
Q2 | $3.18M | Buy |
+57,503
| New | +$3.11M | 0.42% | 47 |
|
|
2017
Q4 | $3.6M | Buy |
58,748
+1,192
| +2% | +$74.6K | 0.51% | 44 |
|
|
2017
Q3 | $3.67M | Sell |
57,556
-1,192
| -2% | -$69.6K | 0.55% | 44 |
|
|
2017
Q2 | $3.27M | Sell |
58,748
-9,000
| -13% | -$490K | 0.5% | 48 |
|
|
2017
Q1 | $3.68M | Buy |
67,748
+1,092
| +2% | +$59.9K | 0.56% | 45 |
|
|
2016
Q4 | $3.9M | Buy |
66,656
+1,878
| +3% | +$103K | 0.65% | 41 |
|
|
2016
Q3 | $3.49M | Buy |
64,778
+1
| +0% | +$64 | 0.61% | 41 |
|
|
2016
Q2 | $4.76M | Buy |
64,777
+2
| +0% | +$141 | 0.87% | 37 |
|
|
2016
Q1 | $4.14M | Buy |
64,775
+462
| +0.7% | +$29.1K | 0.77% | 37 |
|
|
2015
Q4 | $4.42M | Buy |
+64,313
| New | +$4.25M | 0.83% | 40 |
|
|
2015
Q2 | $4.32M | Buy |
64,974
+1,185
| +2% | +$78.1K | 0.74% | 43 |
|
|
2015
Q1 | $4.12M | Sell |
63,789
-95
| -0.1% | -$5.95K | 0.75% | 42 |
|
|
2014
Q4 | $3.77M | Hold |
63,884
| – | – | 0.68% | 43 |
|
|
2014
Q3 | $3.27M | Hold |
63,884
| – | – | 0.62% | 47 |
|
|
2014
Q2 | $3.1M | Buy |
63,884
+5,500
| +9% | +$271K | 0.55% | 49 |
|
|
2014
Q1 | $3.03M | Hold |
58,384
| – | – | 0.57% | 44 |
|
|
2013
Q4 | $3.1M | Hold |
58,384
| – | – | 0.59% | 45 |
|
|
2013
Q3 | $2.7M | Hold |
58,384
| – | – | 0.54% | 49 |
|
|
2013
Q2 | $2.61M | Buy |
+58,384
| New | +$2.53M | 0.55% | 48 |
|
Other funds holding BMY
VCM
VPM
Kimelman & Baird's BMY Position: Q1 2026 in Review
Kimelman & Baird held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 15,525 shares worth $942K. The position accounts for 0.08% of the portfolio, ranked #74.
Kimelman & Baird first reported a position in BMY in Q2 2013 and has held it in 33 quarters since. The position peaked at $4.76M in Q2 2016. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Kimelman & Baird held 15,525 shares of Bristol-Myers Squibb worth $942K as of Q1 2026.
- Kimelman & Baird left its Bristol-Myers Squibb share count unchanged in Q1 2026.
- Bristol-Myers Squibb made up 0.08% of Kimelman & Baird's portfolio in Q1 2026, its #74 holding.
- Kimelman & Baird first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 33 quarters since.
- Kimelman & Baird's Bristol-Myers Squibb position peaked at $4.76M in Q2 2016.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Kimelman & Baird's 13F filing for Q1 2026, filed 13 May 2026.